

Patent

Case No.: 58281US004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:

NOELLE, RANDOLPH J.

Application No.:

10/748010

Group Art Unit:

1653

Filed:

December 30, 2003

Examiner:

Unknown

Title:

IMMUNOSTIMULATORY COMBINATIONS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

31 Aug. 2004

Signed by: Laci Burhop

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. Copies of any cited foreign patents, non-patent literature, and unpublished US application documents are enclosed. Pursuant to the waiver in the Pre-OG Notice, dated July 11, 2003, copies of US patents and published US patent applications are no longer required and are not enclosed. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

If a first Office Action on the merits has been mailed prior to the mailing date of this document, please charge the fee for consideration of an Information Disclosure Statement set forth in 37 CFR § 1.17(p), and if necessary, please charge any additional fees, or credit any overpayment to Deposit Account No. 13-3723.

Respectfully submitted,

Date

Christopher D. Gram, Reg. No.: 43,643

Telephone No.: (651) 733-1507

Office of Intellectual Property Counsel 3M Innovative Properties Company Facsimile No.: 651-736-3833

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 1 of 6

Application Number	10/748,010
Filing Date	December 30, 2003
First Named Inventor	Randolph J. Noelle
Art Unit	1653
Examiner Name	Unknown
Attorney Case Number	58281US004

			U.S. Patent	Documents	
Exam.	Cite	Document Number	Publication Date or Issue Date	Name of Patentee	Pages, Columns, Lines, Where Relevant Passages or Relevant
Init.*	No.	Doc. Number-(Kind Code if Known)	MM-DD-YYYY	or Applicant of Cited Document	Figures Appear
	A1	US- 4,689,338	08-25-1987	Gerster	
	A2	US- 4,698,348	10-06-1987	Gerster	
	A3	US- 4,929,624	05-29-1990	Gerster et al.	
	A4	US- 4,988,815	01-29-1991	Andre et al.	
	A5	US- 5,037,986	08-06-1991	Gerster	
	A6	US- 5,175,296	12-29-1992	Gerster	
	A7	US- 5,238,944	08-24-1993	Wick et al.	
	A8	US- 5,266,575	11-30-1993	Gerster et al.	
	A9	US- 5,268,376	12-07-1993	Gerster	
	A10	US- 5,346,905	09-13-1994	Gerster	
	A11	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A12	US- 5,367,076	11-22-1994	Gerster	
	A13	US- 5,376,501	12-27-1994	Mariën et al.	
	A14	US- 5,389,640	02-14-1995	Gerster et al.	
	A15	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A16	US- 5,446,153	08-29-1995	Lindstrom et al.	
	A17	US- 5,482,936	01-09-1996	Lindstrom	
	A18	US- 5,494,916	02-27-1996	Lindstrom et al.	,
,	A19	US- 5,525,612	06-11-1996	Gerster	
	A20	US- 5,605,899	02-25-1997	Gerster et al.	
	A21	US- 5,693,811	12-02-1997	Lindstrom	
	A22	US- 5,741,908	04-21-1998	Gerster et al.	
	A23	US- 5,756,747	05-26-1998	Gerster	
	A24	US- 5,939,090	08-17-1999	Beaurline et al.	
	A25	US- 6,028,076	02-22-2000	Hirota et al.	
	A26	US- 6,039,969	03-21-2000	Tomai et al.	
	A27	US- 6,069,149	05-30-2000	Nanba et al.	
	A28	US- 6,083,505	07-04-2000	Miller et al.	

*	Ex	a	m	İI	1e	r	•
- 1	ᅜ	ıa.	ш	ш	16		•

Date Considered:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 2 of 6

10/748,010
December 30, 2003
Randolph J. Noelle
1653
Unknown
58281US004

			U.S. Patent	Documents	140
Exam.	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<u> </u>	Doc. Number-(Kind Code if Known)	08-29-2000	Gerster et al.	
	A29	US- 6,110,929	09-05-2000	Johnson et al.	
	A30	US- 6,113,918	02-27-2001	Krieg et al.	
	A31	US- 6,194,388 B1		Gerster et al.	
	A32	US- 6,194,425 B1	02-27-2001		
	A33	US- 6,200,592 B1	03-13-2001	Tomai et al.	
	A34	US- 6,207,646 B1	03-27-2001	Krieg et al.	
	A35	US- 6,239,116 B1	05-29-2001	Krieg et al.	
	A36	US- 6,245,776 B1	06-12-2001	Skwierczynski et al.	
	A37	US- 6,303,347 B1	10-16-2001	Johnson et al.	
	A38	US- 6,323,200 B1	11-27-2001	Gerster et al.	
	A39	US- 6,329,381 B1	12-11-2001	Kurimoto et al.	
	A40	US- 6,331,539 B1	12-18-2001	Crooks et al.	
	A41	US- 6,339,068 B1	01-15-2002	Krieg et al.	
	A42	US- 6,376,501 B1	04-23-2002	Isobe et al.	
	A43	US- 6,376,669 B1	04-23-2002	Rice et al.	
	A44	US- 6,387,938 B1	05-14-2002	Mizuguchi et al.	
	A45	US- 6,406,705 B1	06-18-2002	Davis et al.	
	A46	US- 6,426,334 B1	07-30-2002	Agrawal et al.	
	A47	US- 6,440,992 B1	08-27-2002	Gerster et al.	
	A48	US- 6,476,000 B1	11-05-2002	Agrawal	
	A49	US- 6,451,810 B1	09-17-2002	Coleman et al.	
	A50	US- 6,514,985 B1	02-04-2003	Gerster et al.	
	A51	US- 6,518,265 B1	02-11-2003	Kato et al.	
	A52	US- 6,518,280 B2	02-11-2003	Gerster et al.	
-	A53	US- 6,525,028 B1	02-25-2003	Johnson et al.	
	A54	US- 6,525,064 B1	02-25-2003	Dellaria et al.	
	A55	US- 6,541,485 B1	04-01-2003	Crooks et al.	
	A56	US- 6,545,016 B1	04-08-2003	Dellaria et al.	

*Eva	-	^ ^ r
*Exa	16111	IPPI.
-~~		

Date Considered:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 3 of 6

Application Number	10/748,010
iling Date	December 30, 2003
First Named Inventor	Randolph J. Noelle
rirst Named Inventor	1653
Examiner Name	Unknown
Attorney Case Number	58281US004

				U.S. Patent D		Pages, Columns, Lines, Where Relevant Passages or Relevant
	Cite		Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Figures Appear
Init.*	No.		Number-(Kind Code if Known)	04-08-2003	Dellaria et al.	
	A57		6,545,017 61	05-06-2003	Tomai et al.	
A58 A59			6,558,951 B1	06-03-2003	Crooks et al.	
			- 6,573,273 B1	11-18-2003	Johnson	
	A60 US- 6,649,172 B2 A61 US- 6,656,938 B2 A62 US- 6,660,735 B2 A63 US- 6,660,747 B2 A64 US- 6,664,260 B2 A65 US- 6,664,264 B2 A66 US- 6,664,265 B2 A67 US- 6,667,312 B2 A68 US- 6,670,372 B2 A69 US- 6,677,347 B2			12-02-2003	Crooks et al.	
				12-02-2003	Crooks et al.	
					Crooks et al.	
				12-09-2003	Charles et al.	
					Dellaria et al.	
_				12-16-2003	Crooks et al.	
-			12-16-2003	Bonk et al.		
一			S- 6,667,312 B2	12-23-2003	Charles et al.	
-			12-30-2003	Crooks et al.		
				01-13-2004	Heppner et al.	
	A70) (JS- 6,677,348 B2	01-13-2004	Griesgraber	
1	A7	1 1	US- 6,677,349 B1	01-13-2004		
	A7		US- 6,683,088 B2	01-27-2004		
	A7	- 1	US- 2002/0016332 A1	02-07-2002		
	A7	4	US- 2002/0055517 A1	05-09-2002	t an et al	
\vdash	A	75	US- 2002/0058674 A1	05-16-2002		
t	A	76	US- 2002/0110840 A1	08-15-2002		
\ 	A	77	US- 2003/0133913 A1	07-17-200		
L		78	US- 2003/0139364 A1	07-24-200		
<u> </u>	P	79 US- 2003/0144283 A1				
t		V80	US- 2003/0199461 A1			
t		481	US- 2004/0010007 A1			
ł		A82	US- 2004/0014779 A1	01-22-04	Gordon or an	

	Date Considered:
*Examiner:	is in conformance with MPEP 609. Draw line through citation if not in lext communication to applicant.
EXAMINER: Initial if reference considered, whether or not challed	next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 4 of 6

Application Number	10/748,010
Filing Date	December 30, 2003
First Named Inventor	Randolph J. Noelle
Art Unit	1653
Examiner Name	Unknown
Attorney Case Number	58281US004

			Fc	reign Patent	Documents		
B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21	Cite	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	Translation
		Ctry. Code	Number-KindCode (If known)		Applicant of Cited Document	or Relevant Figures Appear	(Check if yes)
	B1	EP	0 394 026	10-24-1990			X
	B2	EP	1 104 764 A1	06-06-2001			X
	В3	JP	9-208584	08-12-1997			
	B4	JP	11-80156	03-26-1999	(translation only)		X
	B5	JP	11-222432	08-17-1999			Х
	B6	JP	2000-247884 (abstract only)	09-12-2000			×
	В7	wo	00/47719 A2	08-17-2000			Χ .
	B8	wo	00/75304 A1	12-14-2000			×
	В9	wo	00/76505 A1	12-21-2000			Х
	B10	wo	00/76518A1	12-21-2000			Х
	B11	wo	01/74343 A2	10-11-2001			Х
	B12	wo	02/072032	09-19-2002			
	B13	wo	02/36592 A1	05-10-2002			Х
	B14	wo	02/46188 A2	06-13-2002			Х
	B15	wo	02/46189 A2	06-13-2002			Х
	B16	wo	02/46190 A2	06-13-2002			×
	B17	wo	02/46191 A2	06-13-2002			X
	B18	wo	02/46192 A2	06-13-2002			X
-	B19	wo	02/46193 A2	06-13-2002			×
	B20	wo	02/46194 A2	06-13-2002			X
	B21	wo	02/46749 A2	06-13-2002			×
	B22	wo	02/085905 A1	10-31-2002			
	B23	wo	02/102377 A1	12-27-2002			Х
	B24	wo	03/020889 A2	03-13-2003			X
	B25	wo	03/043572 A2	05-30-2003			X
	B26	wo	03/045391 A1	06-05-2003			X
	B27	wo	03/103584 A2	12-18-2003			X

*	F	v	9	m	i	n	_	r	•
	_	x	м	111		n	н		

Date Considered:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 5 of 6

Application Number	10/748,010
Filing Date	December 30, 2003
First Named Inventor	Randolph J. Noelle
Art Unit	1653
Examiner Name	Unknown
Attorney Case Number	58281US004

		OTHER ROCHMENTS (Including Authors Title Red Red Research Rouse Act)			
	OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)				
	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	C1	Testerman, et al., "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", <u>Journal of Leukocyte Biology</u> , Volume 58, pp. 365-372, September 1995.			
	C2	Chollet, et al, "Development of a Topically Active Imiquimod Formulation", <u>Pharmaceutical Development and Technology</u> , 4(1), pp 35-43 (1999)			
	C3	Brassard et al.; "Interferon-α as an immunotherapeutic protein"; Journal of Leukocyte Biology; Vol. 71; April 2002; pgs. 565-581			
	C4	Izumi et al.; "1 <i>H</i> -imidazo[4,5- <i>c</i>]quinoline Derivatives as Novel Potent TNF-α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2-and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolines or 1 <i>H</i> -imidazo[4,5- <i>c</i>]pyridines"; Bioorganic and Medicinal Chemistry, Vol. 11, pp. 2541-2550 (2003).			
	C5	Hornung et al., "Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides ¹ ", <u>The Journal of Immunology</u> , 2002, 168; pgs. 4531-4537.			
	C6	Hemmi et al., "Small anti-viral compounds activate immune cells <i>via</i> the TLR7 MyD88-dependent Signaling pathway", Nature Immunology, vol. 3, no. 2; February 2002; pgs. 196-200.			
	C7	Medzhitov, "Toll-Like Receptors and Innate Immunity", <u>Nature Reviews Immunology</u> , Vol. 1; November 2001, pgs. 135-145.			
	C8	Jurk et al. "Human TLR7 and TLR8 independently confer responsiveness to the antiviral compound R-848", Nature Immunology, June 2002, vol. 3, no. 6; pg. 1.			
	C9	Akira et al., "Toll-like receptors: critical proteins linking innate and acquired immunity", Nature Immunology, August 2001, vol. 2, no. 8; pgs. 675-680			
C	C10	Heil et al.; "Synthetic immunostimulatory compounds activate immune cells via TLR7 and TLR8"; 33th Annual Meeting of the Deutsche Gessellschaft für Immunologie, Marburg 2002 - Abstract C.6			
C	211	Takeuchi et al.; "Discrimination of bacterial lipoproteins by Toll-like receptor 6", International Immunology, March, 2001, Vol. 13, No. 7, pp. 933-940.			
C	C12	Maxwell et al,; "Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity", <u>J. Immunol.</u> , May 2002; Vol. 168, pp. 4372-4381.			
C	C13	Maxwell et al, Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion, J. Immunol., Jan. 2000; Vol. 164, pp. 107-112.			
C	C14	Lamprecht et al.; "Heterogeneity of CD4+ and CD8+ Memory T Cells in Localized and Generalized Wegener's Granulomatosis", Arthritis Res. and Ther., 2003; Vol. 5, pp. R25-R31.			
C	215	Mackay,; "Dual Personality of Memory T cells", Nature, 1999; Vol. 401, pp. 659-660.			
C	C16	Weninger et al.; Migratory Properties of Naïve, Effector, and Memory CD8+ T Cell, <u>J. Exp. Med.</u> , Oct. 2001; Vol. 194, No. 7, pp. 953-966.			
C	C17	Faint et al,; "Memory T Cells Constitute a Subset of the Human CD8+CD45RA+ Pool with Distinct Phenotypic and Migratory Characteristics", <u>J. Immunol.</u> , 2001, Vol. 167, pp. 212-220.			
C	C18	Kedl et al.; "CD40 Stimulation Accelerates Deletion of Tumor-Specific CD8+ T Cells in the Absence of Tumor-Antigen Vaccination", Proc. Nat. Acad. Sci., Sept. 2001; Vol. 98, No. 19, pp. 10811-10816.			
*Exami	ner:	Date Considered:			

*Examiner:

Date Considered:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 6 of 6

Application Number	10/748,010
Filing Date	December 30, 2003
First Named Inventor	Randolph J. Noelle
Art Unit	1653
Examiner Name	Unknown
Attorney Case Number	58281US004

		OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C19	Kedl et al, "T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells", <u>J. Exp. Med.,</u> Vol. 192, No. 8, pp. 1105-1113.

*Examiner:

Date Considered: